

**ACTION:** Notice of Receipt of Notice of Entitlement under section 2105 of the FDA Export Reform and Enhancement Act of 1996 (Chapter 1A of Pub. L. No. 104-134).

**SUMMARY:** The Patent and Trademark Office has received notification from G. D. Searle & Co. that it claims entitlement under section 2105 of the FDA Export Reform and Enhancement Act of 1996 (Chapter 1A of Pub. L. No. 104-134) for its drug product DAYPRO—oxaprozin.

**FOR FURTHER INFORMATION CONTACT:** Karin Tyson by telephone at (703) 305-9285; by mail marked to her attention and addressed to the Assistant Commissioner for Patents, Box DAC, Washington, D.C. 20231; or by fax marked to her attention at (703) 308-6916.

**SUPPLEMENTARY INFORMATION:** On April 25, 1996, the FDA Export Reform and Enhancement Act of 1996 (Act) (Chapter 1A of Pub. L. No. 104-134) was enacted. Section 2105 thereof grants specified exclusive rights to the owner of the right to market a specified nonsteroidal anti-inflammatory drug who has complied with the Act. The text of Section 2105 is as follows:

(a) In General.—Any owner on the date of enactment of this Act of the right to market a nonsteroidal antiinflammatory drug that—

(1) contains a previously patented active agent;

(2) has been reviewed by the Federal Food and Drug Administration for a period of more than 120 months as a new drug application; and

(3) was approved as safe and effective by the Federal Food and Drug Administration on October 29, 1992, shall be entitled, for the 2-year period beginning on October 29, 1997, to exclude others from making, using, offering for sale, selling, or importing into the United States such active agent, in accordance with section 154(a)(1) of title 35, United States Code.

(b) Infringement.—Section 271 of title 35, United States Code shall apply to the infringement of the entitlement provided under subsection (a). No application described in section 271(e)(2)(A) of title 35, United States Code, regardless of purpose, may be submitted prior to the expiration of the entitlement provided under subsection (a).

(c) Notification.—Not later than 30 days after the date of enactment of this Act, any owner granted an entitlement under subsection (a) shall notify the Commissioner of Patents and Trademarks and the Secretary of Health and Human Services of such

entitlement. Not later than 7 days after receipt of such notice, the Commissioner and Secretary shall publish an appropriate notice of the receipt of such notice.

On May 15, 1996, G. D. Searle & Co., filed a notice with the Commissioner of Patents and Trademarks of its claim for entitlement pursuant to Section 2105(c) of the Act. The notice states that G. D. Searle & Co. was the owner of the right to market the nonsteroidal antiinflammatory drug oxaprozin on April 25, 1996, the date of enactment of the Act. Further, the notice states: that oxaprozin contains an agent that was patented and covered by U.S. Patent No. 3,578,671; that a New Drug Application (NDA) was filed on August 10, 1982 for oxaprozin and was reviewed for a period of more than 120 months; and that oxaprozin was approved as safe and effective by the Federal Food and Drug Administration on October 29, 1992.

Dated: May 16, 1996.

Bruce A. Lehman,

*Assistant Secretary of Commerce and  
Commissioner of Patents and Trademarks.*

[FR Doc. 96-12882 Filed 5-21-96; 8:45 am]

BILLING CODE 3510-16-U

## COMMODITY FUTURES TRADING COMMISSION

### Chicago Mercantile Exchange Proposed Futures and Option Contracts on the Taiwan Stock Index

**AGENCY:** Commodity Futures Trading Commission.

**ACTION:** Notice of availability of the terms and conditions of proposed commodity futures contract.

**SUMMARY:** The Chicago Mercantile Exchange (CME or Exchange) has applied for designation as a contract market in futures and futures options on the Taiwan Stock Index. The Acting Director of the Division of Economic Analysis (Division) of the Commission, acting pursuant to the authority delegated by Commission Regulation 140.96, has determined that publication of the proposal for comment is in the public interest, will assist the Commission in considering the views of interested persons, and is consistent with the purposes of the Commodity Exchange Act.

**DATES:** Comments must be received on or before June 21, 1996.

**ADDRESSES:** Interested persons should submit their views and comments to Jean A. Webb, Secretary, Commodity Futures Trading Commission, Three Lafayette Centre, 1155 21st St., NW.,

Washington, DC 20581. Reference should be made to the Chicago Mercantile Exchange Taiwan Stock Index futures and option contracts.

**FOR FURTHER INFORMATION CONTACT:** Please contact Stephen Sherrod of the Division of Economic Analysis, Commodity Futures Trading Commission, Three Lafayette Centre, 1155 21st St., NW., Washington, DC 20581, telephone 202-418-5277.

**SUPPLEMENTARY INFORMATION:** Copies of the terms and conditions will be available for inspection at the Office of the Secretariat, Commodity Futures Trading Commission, Three Lafayette Centre, 1155 21st St., NW., Washington, DC 20581. Copies of the terms and conditions can be obtained through the Office of the Secretariat by mail at the above address or by phone at (202) 418-5097.

Other materials submitted by the CME in support of the application for contract market designation may be available upon request pursuant to the Freedom of Information Act (5 U.S.C. 552) and the Commission's regulations thereunder (17 CFR Part 145 (1987)), except to the extent they are entitled to confidential treatment as set forth in 17 CFR 145.5 and 145.9. Requests for copies of such materials should be made to the FOI, Privacy and Sunshine Act Compliance Staff of the Office of the Secretariat at the Commission's headquarters in accordance with 17 CFR 145.7 and 145.8.

Any person interested in submitting written data, views, or arguments on the proposed terms and conditions, or with respect to other materials submitted by the CME, should send such comments to Jean A. Webb, Secretary, Commodity Futures Trading Commission, Three Lafayette Centre, 1155 21st St., NW., Washington, DC 20581 by the specified date.

Issued in Washington, DC, on May 16, 1996.

Blake Imel,

*Acting Director.*

[FR Doc. 96-12820 Filed 5-21-96; 8:45 am]

BILLING CODE 6351-01-P

## Meetings; Sunshine Act

**AGENCY HOLDING THE MEETING:** Commodity Futures Trading Commission.

**TIME AND DATE:** 11:00 a.m., Friday, June 7, 1996.

**PLACE:** 1155 21st St. N.W., Washington, D.C. 9th Floor Conference Room.

**STATUS:** Closed.

**MATTERS TO BE CONSIDERED:** Surveillance Matters.